Pacira BioSciences Stock Forecast

Stock Price Forecast

According to 6 analysts polled by S&P Global, Pacira BioSciences stock has a consensus rating of "Buy" and an average price target of $29.67. The average 1-year stock price forecast is 18.02% higher than the current stock price, while the lowest is $23 (-8.51%) and the highest is $38 (+51.15%).

Price Target: $29.67 (+18.02%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$23	$29.67	$28.5	$38
Change	-8.51%	+18.02%	+13.37%	+51.15%

Analyst Ratings

The average analyst rating for Pacira BioSciences stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Feb '26	Mar '26	Apr '26	May '26	Jun '26	Jul '26
Strong Buy	3	3	3	3	2	2
Buy	1	1	1	1	1	1
Hold	2	2	2	2	2	2
Sell	1	1	1	1	1	1
Strong Sell	0	0	0	0	0	0
Total	7	7	7	7	6	6

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Douglas Tsao H.C. Wainwright	H.C. Wainwright	Buy Reiterates $38	Buy	Reiterates	$38	+51.15%	Jul 1, 2026
Serge Belanger Needham	Needham	Buy Maintains $32	Buy	Maintains	$32	+27.29%	Jun 30, 2026
Jenna Davidner Barclays	Barclays	Hold Maintains $25	Hold	Maintains	$25	-0.56%	May 14, 2026
Les Sulewski Truist Financial	Truist Financial	Buy Maintains n/a	Buy	Maintains	n/a	n/a	May 1, 2026
Douglas Miehm RBC Capital	RBC Capital	Hold Maintains $22 → $24	Hold	Maintains	$22 → $24	-4.53%	May 1, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

767.79M

from 726.41M

5.70%

from 726.41M

Revenue Next Year

831.29M

from 767.79M

8.27%

from 767.79M

EPS This Year

2.88

from 2.65

8.57%

from 2.65

EPS Next Year

3.65

from 2.88

26.79%

from 2.88

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	541.53M	666.82M	674.98M	700.97M	726.41M	767.79M
Revenue Growth	26.04%	23.14%	1.22%	3.85%	3.63%	5.70%
Gross Profit	401.28M	467.53M	490.31M	530.54M	576.66M	606.81M
Gross Margin	74.10%	70.11%	72.64%	75.69%	79.39%	79.03%
Operating Income	89.92M	70.93M	87.32M	97.57M	33.30M	158.41M
Net Income	41.98M	15.91M	41.96M	-99.56M	7.03M	36.63M
EPS	-	-	-	-	2.65	2.88
EPS Growth	-	-	-	-	-17.19%	8.57%
Forward PE	15.43	11.64	10.23	7.10	7.53	8.74
Free Cash Flow	49.79M	92.00M	107.15M	163.38M	108.56M	157.00M
No. Analysts	-	-	-	-	-	5

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	769.0M
Avg	767.8M
Low	766.5M

Revenue Growth

Revenue Growth	2026	2027	2028
High	5.9%
Avg	5.7%
Low	5.5%

EPS Forecast

EPS	2026	2027	2028
High	2.98
Avg	2.88
Low	2.74

EPS Growth

EPS Growth	2026	2027	2028
High	12.5%
Avg	8.6%
Low	3.3%